title: Buprenorphine alone and in combination with naloxone in non-dependent humans.
abstract: This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonist-antagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.
authors.affiliation: Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland.
authors.forename: L L
authors.initials: LL
authors.lastname: Weinhold
authors.forename: K L
authors.initials: KL
authors.lastname: Preston
authors.forename: M
authors.initials: M
authors.lastname: Farre
authors.forename: I A
authors.initials: IA
authors.lastname: Liebson
authors.forename: G E
authors.initials: GE
authors.lastname: Bigelow
mesh_terms: D000328:Adult; D002047:Buprenorphine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000494:pharmacology*; D019966:Substance-Related Disorders; D013647:Task Performance and Analysis
chemical_list: D004338:Drug Combinations; D009270:Naloxone; D002047:Buprenorphine